Group One Trading Adds $7M in Absci Corporation ($ABSI)
Key Points
- Wall Street's consensus rating on $ABSI is Strong Buy and an average price target of $9.11.
- $ABSI last traded around $6.51.
Group One Trading acquired a new position in Absci Corporation ($ABSI), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,131,988 shares of Absci Corporation. Group One Trading's holdings in Absci Corporation were worth $7.37 million as of its most recent filing.
Absci Corporation ($ABSI) Stock
Absci Corporation Earnings
Analysts Set New Price Targets
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.